bioAffinity Technologies Unveils Sputum Test Data for Asthma and COPD at CHEST 2026
Event summary
- bioAffinity Technologies will present data on a sputum-based test for lung inflammation at CHEST 2026 on October 20.
- The test measures key cytokines and cell-surface receptors linked to asthma and COPD, including targets of approved biologic therapies.
- Data show the test can detect multiple inflammatory markers in sputum using flow cytometry and AI.
- The test is not yet available for clinical or diagnostic use and remains investigational.
The big picture
bioAffinity Technologies' sputum-based test aims to provide a more detailed picture of lung inflammation, potentially guiding treatment decisions for asthma and COPD. The global asthma therapeutics market is projected to reach $47.6 billion by 2034, driven by the growing range of biologic therapies targeting specific inflammatory pathways. The test could support a precision medicine approach, helping identify patients who may benefit from specific biologic therapies.
What we're watching
- Clinical Validation
- Whether the test can be validated for clinical use and gain regulatory approval.
- Market Adoption
- The pace at which the test could be adopted by clinicians for asthma and COPD management.
- Competitive Positioning
- How bioAffinity Technologies positions this test against existing diagnostic tools in the asthma and COPD space.
Related topics
